Pembrolizumab for Early Triple-Negative Breast Cancer. Reply
N Engl J Med
.
2020 Jun 25;382(26):e108.
doi: 10.1056/NEJMc2006684.
Authors
Peter Schmid
1
,
Rebecca Dent
2
,
Joyce O'Shaughnessy
3
Affiliations
1
Queen Mary University of London, London, United Kingdom p.schmid@qmul.ac.uk.
2
National Cancer Center Singapore, Singapore, Singapore.
3
US Oncology, Dallas, TX.
PMID:
32579835
DOI:
10.1056/NEJMc2006684
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
Breast Neoplasms*
Humans
Triple Negative Breast Neoplasms*
Substances
Antibodies, Monoclonal, Humanized
pembrolizumab